Roche Launches Tecentriq SC in India, Bringing 7-Minute Immunotherapy to Lung Cancer Care

Tecentriq, whose generic name is atezolizumab, is a cancer immunotherapy. Roche India describes it as a monoclonal antibody designed to target PD-L1 proteins found on tumour cells and tumour-infiltrating immune cells. By blocking the PD-L1 pathway, the drug is intended to help the immune system recognise and attack cancer cells more effectively. Roche India lists approved indications for Tecentriq including metastatic non-small cell lung cancer, extensive-stage small cell lung cancer, triple-negative breast cancer, hepatocellular carcinoma and metastatic urothelial carcinoma. The post Roche Launches Tecentriq SC in India, Bringing 7-Minute Immunotherapy to Lung Cancer Care appeared first on Dharmakshethra – India Unabridged .